Locked onto EGFRvIII- and Glypican-3 (GPC3), the new version of CAR-iMACs polarised with LPS stimulation seems to be resistant to the immunosuppressive effect of the TME and are conferred with an ameliorated adhesive nature and displayed a strong anti-cancer effect on EGFRvIII+ U87MG-human glioblastoma cell lines compared to WT or first-generation CAR-iMACs. This evidence concerns the gene GPC3 and cancer.